Novartis and Genentech Sue Over Alleged Illegal Importation of Xolair

Swiss pharmaceutical giant Novartis and its subsidiary Genentech have initiated legal proceedings against SHARx, an alternative funding program, and a Canadian pharmacy. The lawsuit, filed on February 2, 2026, in U.S. District Court in Michigan, alleges that these entities are involved in a scheme to illegally import Xolair, an injectable medication used to treat severe asthma, food allergies, and respiratory conditions, from Canada into the United States. The plaintiffs argue that this importation violates U.S. Food and Drug Administration (FDA) regulations, which prohibit the importation of unapproved medications from overseas.

CNBCNovartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195th

The lawsuit emphasizes the risks associated with the importation of biological medicines like Xolair, which require strict shipping and temperature controls to maintain their safety and efficacy. Novartis and Genentech contend that improper handling could lead to contamination and degradation of the medication, posing significant health risks to patients.

Novartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195th

This legal action highlights the growing concerns surrounding alternative funding programs (AFPs), which have emerged as a response to the high costs of specialty medications. These programs often contract with employer-sponsored health plans to provide more affordable access to medications, but they frequently operate in a legal gray area. Federal authorities have previously warned that importing medications from foreign markets could compromise drug quality and public health.

Novartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195th

The lawsuit reflects ongoing tensions within the pharmaceutical industry regarding drug pricing and access. While Novartis aims to protect the integrity of its supply chain and adhere to regulatory frameworks, patient advocacy groups and healthcare providers may view AFPs as essential tools for mitigating costs for vulnerable populations. This duality between regulatory compliance and affordability remains a contentious issue.

Novartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195th

Following the announcement of the lawsuit, Novartis' shares fell by 0.80%, closing at $163.42 on February 26, 2026. Analysts have noted that this decline reflects investor concerns over the immediate legal challenges and regulatory scrutiny facing the company, overshadowing its long-term strategic initiatives. Despite Novartis' robust fundamentals and a recent $23 billion investment in radioligand therapies, the lawsuit has raised questions about the potential impact on the company's reputation and operational costs.

Novartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195thCNBC

If the court rules in favor of Novartis, it could set a precedent for stricter enforcement of FDA importation rules, potentially deterring similar practices in the industry. Conversely, if the case is challenged or delayed, Novartis may face prolonged legal expenses and reputational damage.

Novartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195th

Novartis has reiterated its commitment to maintaining regulatory compliance and ensuring patient safety. The company stated that "biological medicines require particular care" due to their complex composition and sensitivity to variations in storage and handling conditions.

Novartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195th

While Novartis and Genentech assert that the importation of Xolair poses significant risks, the perspective of patient advocacy groups on the necessity of AFPs remains underrepresented in the current discourse. Further insights from these groups could provide a more comprehensive understanding of the implications of the lawsuit.

Novartis Shares Fall 0.8% Amid FDA Lawsuit Over Xolair Imports Trading Volume Ranks 195th

“Biological medicines, like the U.S. Xolair medicine, require particular care because their complex composition and sensitivity to variation in storage and handling conditions are susceptible to contamination and degradation that could undermine their safety and efficacy,” — Novartis Statement

CNBC

“Federal authorities told CNBC last year that importing medications from foreign markets is illegal and could pose risks to patients' health.” — Federal Authorities Statement

CNBC